Markers of systemic inflammation
In patients randomized to spesolimab and who had an elevated neutrophil count that was above ULN at baseline (7.23 × 10Median absolute values from baseline over time in neutrophil count (a), CRP levels (b), and serum albumin levels (c) for patients in the spesolimab group who had abnormal count/levels at baseline. Data are shown for patients initially randomized to receive spesolimab who received up to two doses of spesolimab. (a) Data for seven patients who had baseline neutrophil counts above the ULN of 7.23 × 10